Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration

Published:2013-05-01 Issue:4 Volume:13 Page:444-459
ISSN:1568-0096
Container-title:Current Cancer Drug Targets
language:en
Short-container-title:CCDT

Author:

Shiota Masaki,Yokomizo Akira,Fujimoto Naohiro,Kuruma Hidetoshi,Naito Seiji

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Drug Discovery,Pharmacology,Oncology

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors;Cancer Science;2023-01-20

2. A Phase II Trial of Abiraterone With Dutasteride for Second‐Generation Antiandrogen‐ and Chemotherapy‐Naïve Patients With Castration‐Resistant Prostate Cancer;The Journal of Clinical Pharmacology;2023-01-17

3. Impact of antiandrogen withdrawal syndrome in castration‐resistant prostate cancer patients treated with abiraterone or enzalutamide;International Journal of Urology;2020-09-15

4. High‐throughput screen identifies 5‐HT receptor as a modulator of AR and a therapeutic target for prostate cancer;The Prostate;2020-06

5. Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer;Anticancer Research;2018-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP